Yang Meng, Liu Xia, Chen Yinghua, Chen Xin, Xu Feng, Liu Zhengzhao, Zhang Haitao, Zeng Caihong, Hu Weixin
National Clinical Research Center of Kidney Diseases, Jinling Clinical Medical College of Nanjing Medical University, Nanjing, China.
Jiangsu Health Vocational College, Nanjing, China.
J Nephrol. 2025 Jan;38(1):215-224. doi: 10.1007/s40620-024-02134-z. Epub 2024 Nov 22.
Anti-neutrophil cytoplasmic antibody (ANCA) Renal Risk Score has not been widely validated in Chinese patients with myeloperoxidase -ANCA-associated glomerulonephritis and its predictive ability needs to be improved.
Three hundred and forty patients with biopsy-proven myeloperoxidase-ANCA-associated glomerulonephritis were included in this study. They were divided into an oliguric group (urine volume < 400 ml/24 h) and a non-oliguric group (urine volume ≥ 400 ml/24 h). The ANCA Renal Risk Score and Berden classes were used to predict the risk of end-stage kidney disease (ESKD), and Cox regression analysis was performed to evaluate the impact of oliguria on ESKD risk.
The predictive performance of ANCA Renal Risk Score was significantly higher than that of Berden classes (AUC: 0.79 vs. 0.709, P = 0.003). Thirty-six (10.6%) patients presented with oliguria. Patients in the oliguric group had significantly lower levels of baseline estimated glomerular filtration rate (eGFR) [6.51(4.55-7.72) vs. 21.22(11.49-36.63) ml/min/1.73 m, P < 0.001], hemoglobin (78.33 ± 16.75 vs. 92.47 ± 18.95 g/L, P < 0.001), serum albumin (32.01 ± 5.92 vs. 36.22 ± 4.84 g/L, P < 0.001), and a lower percentage of normal glomeruli [6.86(0-17.39)% vs. 18.18(9.09-35)%, P < 0.001]. Consistently, the oliguric group had a higher percentage of patients that progressed to ESKD (83.3% vs. 36.2%, P < 0.001). Multivariate Cox regression analysis showed that oliguria was an independent risk factor for ESKD [HR = 2.38(1.39-4.06), P = 0.002]. Oliguria scores (3 points for presence and 0 for absence) were incorporated into the ANCA Renal Risk Score, resulting in ANCA Renal Risk Score-U. The patients were then categorized into four risk groups: low-(0-2 points), moderate-(3-7 points), high-(8-11 points) and very high-(12-14 points). The incidences of ESKD in these groups were 11.1%, 30%, 72.2% and 95.8%, respectively. The predictive efficacy of ANCA Renal Risk Score-U in predicting ESKD risk was significantly higher than that of the ANCA Renal Risk Score (AUC: 0.812 vs. 0.79, P = 0.025).
This study has validated the ANCA Renal Risk Score for predicting kidney outcomes among Chinese patients with myeloperoxidase-ANCA-associated glomerulonephritis. Furthermore, the ANCA Renal Risk Score-U model with oliguria as a variable can further improve the prediction of ESKD risk in patients with myeloperoxidase-ANCA-associated glomerulonephritis.
抗中性粒细胞胞浆抗体(ANCA)肾脏风险评分在中国髓过氧化物酶-ANCA相关性肾小球肾炎患者中尚未得到广泛验证,其预测能力有待提高。
本研究纳入340例经活检证实的髓过氧化物酶-ANCA相关性肾小球肾炎患者。他们被分为少尿组(尿量<400ml/24小时)和非少尿组(尿量≥400ml/24小时)。使用ANCA肾脏风险评分和伯登分级来预测终末期肾病(ESKD)风险,并进行Cox回归分析以评估少尿对ESKD风险的影响。
ANCA肾脏风险评分的预测性能显著高于伯登分级(AUC:0.79对0.709,P = 0.003)。36例(10.6%)患者出现少尿。少尿组患者的基线估计肾小球滤过率(eGFR)水平显著更低[6.51(4.55-7.72)对21.22(11.49-36.63)ml/min/1.73m²,P<0.001]、血红蛋白水平(78.33±16.75对92.47±18.95g/L,P<0.001)、血清白蛋白水平(32.01±5.92对36.22±4.84g/L,P<0.001),且正常肾小球的比例更低[6.86(0-17.39)%对18.18(9.09-35)%,P<0.001]。同样,少尿组进展为ESKD的患者比例更高(83.3%对36.2%,P<0.001)。多因素Cox回归分析显示少尿是ESKD的独立危险因素[HR = 2.38(1.39-4.06),P = 0.002]。将少尿评分(存在为3分,不存在为0分)纳入ANCA肾脏风险评分,得到ANCA肾脏风险评分-U。然后将患者分为四个风险组:低风险组(0-2分)、中风险组(3-7分)、高风险组(8-11分)和极高风险组(12-14分)。这些组中ESKD的发生率分别为11.1%、30%、72.2%和95.8%。ANCA肾脏风险评分-U预测ESKD风险的效能显著高于ANCA肾脏风险评分(AUC:0.812对0.79,P = 0.025)。
本研究验证了ANCA肾脏风险评分在预测中国髓过氧化物酶-ANCA相关性肾小球肾炎患者肾脏结局中的作用。此外,以少尿为变量的ANCA肾脏风险评分-U模型可进一步提高髓过氧化物酶-ANCA相关性肾小球肾炎患者ESKD风险的预测能力。